Trusted Resource for Clinical Trials, Protocols & Progress
Clinical supply logistics are a critical yet often underappreciated component of clinical trial execution. In ultra-rare disease trials, this complexity is magnified by limited availability of the investigational product (IP), small and geographically dispersed patient populations, highly specialized storage conditions, and strict regulatory import/export requirements.
Click to read the full article.
The U.S. Orphan Drug Act (ODA) of 1983 was enacted to stimulate the development of therapies for rare diseases — defined as conditions affecting fewer than 200,000 individuals in the United States. One of its key incentives is the grant of **7 years of market exclusivity** for approved orphan-designated drugs. This exclusivity prevents the FDA from approving any other application for the same drug for the same indication, even in the absence of patent protection.
Click to read the full article.
Rare cancers, such as sarcomas, pediatric malignancies, and ultra-rare leukemias, represent one of the most challenging landscapes in drug development. Traditional randomized controlled trials requiring hundreds or thousands of patients are often impossible due to extremely limited patient pools. In some instances, only a few dozen eligible patients may exist worldwide at a given time. To address these challenges, innovative trial designs, adaptive endpoints, and international collaboration have enabled regulatory approvals for therapies in these ultra-rare oncology settings.
Click to read the full article.
In rare disease clinical trials—especially those involving children or patients with significant physical or cognitive limitations—caregivers are not just companions; they are essential stakeholders. They manage medications, attend site visits, communicate with physicians, and navigate the daily burdens of the disease alongside the patient.
Click to read the full article.
Contract negotiation is a foundational component of clinical trial startup. In global rare disease studies, the negotiation process is uniquely complex due to limited site experience, small budgets, multinational regulations, and urgent timelines. These trials often involve sponsors with limited commercial infrastructure and rely heavily on academic institutions, hospitals, or rare disease centers of excellence—which may not have streamlined contracting practices.
Click to read the full article.
Developing therapies for rare diseases presents significant financial challenges. With small patient populations, limited market sizes, and complex trial designs, the return on investment is often uncertain. To bridge this gap, governments and regulatory agencies provide a range of financial incentives — including tax credits and development grants — aimed at encouraging investment in orphan drug research.
Click to read the full article.
Rare disease clinical trials face the unique challenge of enrolling very small patient populations, often fewer than a few hundred globally. Traditional endpoints such as overall survival, large-scale quality-of-life metrics, or long-term morbidity markers are frequently impractical. To address this challenge, regulatory agencies like the FDA and EMA have accepted novel endpoints, including surrogate markers, functional outcomes, and patient-reported measures. These endpoints allow researchers to demonstrate efficacy within feasible timelines, while still meeting the rigorous standards required for drug approval.
Click to read the full article.
Informed assent is the process through which children, who are legally not able to give full informed consent, are involved in the decision to participate in clinical research. While legal guardians provide formal consent, children should still be given age-appropriate information and the opportunity to express willingness—or unwillingness—to participate.
Click to read the full article.
A Pediatric Investigation Plan (PIP) is a regulatory requirement in the European Union (EU) for all new medicines, including those intended for rare diseases. Administered by the European Medicines Agency (EMA), PIPs aim to ensure that medicines developed for adults are also evaluated for their potential use in children, unless a waiver or deferral is granted.
Click to read the full article.
In the traditional research paradigm, patients are often passive participants, enrolled in studies designed and managed by pharmaceutical sponsors or academic investigators. Rare disease research challenges this model. With limited commercial incentives and scarce clinical expertise, patients and families frequently take on leadership roles, catalyzing initiatives that would otherwise never reach the clinical trial stage. Patient-led research has emerged as a powerful model, leveraging community-driven registries, advocacy networks, and grassroots fundraising to fill gaps left by industry and government.
Click to read the full article.
